Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/01/2873078/0/en/Apellis-Announces-11-Oral-Presentations-at-the-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/26/2870392/0/en/Apellis-Announces-Pegcetacoplan-MAA-Review-Has-Been-Reset-to-Day-180-of-Initial-Assessment-by-European-Medicines-Agency-EMA.html
https://www.globenewswire.com/news-release/2024/04/23/2867517/0/en/Apellis-Pharmaceuticals-to-Host-Conference-Call-on-May-7-2024-to-Discuss-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/04/04/2858191/0/en/Apellis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/04/01/2855079/0/en/Apellis-Pharmaceuticals-to-Host-a-Fireside-Chat-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2024/03/11/2843618/0/en/Apellis-Appoints-Leading-Expert-Dr-Philip-Ferrone-as-Chief-Medical-Retina-Advisor.html
https://www.globenewswire.com//news-release/2024/03/06/2841772/0/en/Apellis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.fiercepharma.com/pharma/apellis-cites-current-challenges-syfovre-launch-bright-prospects-long-term
https://www.globenewswire.com//news-release/2024/02/27/2835873/0/en/Apellis-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/26/2834993/0/en/Apellis-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences.html